
J&J Q1 Earnings Beat Estimates Despite Stelara Sales Decline
Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations, driven by robust sales of key pharmaceuticals. The company posted $24.1 billion in revenue, up nearly 10% year-over-year, and reported adjusted EPS of $2.70. Growth was primarily fueled by strong demand for Darzalex and Tremfya, which significantly outperformed analyst predictions. However, the quarter was marked by a steep decline in Stelara sales, which lost patent protection and faced biosimilar competition. Despite this challenge, J&J raised its full-year 2026 revenue forecast to $100.8 billion. Furthermore, the company voiced concerns over proposed MFN drug pricing deals, warning that such policies could negatively impact patient access and innovation.






















